Abstract
Chemotherapy is standard therapy for metastatic disease. However, aggressive local therapies may improve outcomes for selected patients (pts) with oligometastatic disease. SBRT in early stage non-small cell lung cancer (NSCLC) has high rates of local control (LC), but little data exist assessing SBRT to treat lung metastases. We assess safety and efficacy of SBRT in pts with 1-5 pulmonary metastases and limited extrathoracic disease, and we compare outcomes by disease. We hypothesized SBRT to lung metastases could achieve high LC across diverse primary tumor types, and overall survival (OS) would vary by disease site of origin and time from stage IV diagnosis.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
